Clinical Development of Immunotherapy for Small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2018.12.10
- Author:
Tao YU
1
;
Diansheng ZHONG
1
Author Information
1. Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Journal Article
- Keywords:
Clinical development;
Immunotherapy;
Lung neoplasms
- MeSH:
Humans;
Immunologic Factors;
genetics;
immunology;
Immunotherapy;
methods;
trends;
Lung Neoplasms;
genetics;
immunology;
therapy;
Programmed Cell Death 1 Receptor;
genetics;
immunology;
Small Cell Lung Carcinoma;
genetics;
immunology;
therapy
- From:
Chinese Journal of Lung Cancer
2018;21(12):918-923
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC), which accounts for about 15% of lung cancer cases, is an aggressive disease characterized by rapid growth and early widespread metastasis. Despite sensitive to chemotherapy and radiotherapy, SCLC is vulnerable to get resistant and has high recurrence rates. In recent years, immunotherapy has shown good antitumor activity, especially programmed death receptor-1/ligand-L1 (PD-1/L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) Checkpoint inhibitors have changed the pattern of tumor treatment, and SCLC has high immunogenicity, high mutation load and other favorable immune factors, so immuno-checkpoint inhibitors may become an important breakthrough in SCLC treatment. This article will briefly review the clinical research of immunotherapy for small cell lung cancer.
.
